Fosamax Fractures-Justice Has Not Been Served.

Curfman, Gregory

Curfman, Gregory.

Affiliation

Curfman G; Executive Editor, JAMA , Chicago, Illinois.

JAMA ; 331(22): 1887-1888, 2024 06 11.

Article in En | MEDLINE | ID: mdl-38748439

This Viewpoint discusses the ongoing lawsuit between plaintiffs who had been affected by atypical femoral fractures while receiving alendronate and the drug manufacturer.

Subject(s)

Alendronate; Bone Density Conservation Agents; Drug Labeling; Fractures, Bone; Hip Fractures; Humans; Fractures, Bone/chemically induced; Fractures, Bone/prevention & control; United States; United States Food and Drug Administration/legislation & jurisprudence; United States Food and Drug Administration/standards; Alendronate/adverse effects; Alendronate/pharmacology; Alendronate/therapeutic use; Bone Density Conservation Agents/adverse effects; Bone Density Conservation Agents/pharmacology; Bone Density Conservation Agents/therapeutic use; Hip Fractures/chemically induced; Hip Fractures/physiopathology; Bone Remodeling/drug effects; Fractures, Spontaneous/chemically induced; Fractures, Spontaneous/physiopathology; Drug Approval/legislation & jurisprudence; Drug Labeling/legislation & jurisprudence; Drug Labeling/standards

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alendronate / Drug Labeling / Fractures, Bone / Bone Density Conservation Agents / Hip Fractures Limits: Humans Country/Region as subject: America do norte Language: En Journal: JAMA Year: 2024 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google